End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
65,300 KRW | +0.62% | -0.46% | -5.50% |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- For the past twelve months, EPS forecast has been revised upwards.
Weaknesses
- The company is not the most generous with respect to shareholders' compensation.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-5.50% | 422M | - | ||
+10.23% | 9.11B | A- | ||
-10.76% | 5.21B | A- | ||
+53.60% | 4.83B | - | ||
+7.56% | 4.09B | B- | ||
-21.42% | 2.35B | C- | ||
+13.92% | 2.32B | B | ||
+25.03% | 2.27B | - | - | |
-30.36% | 2.19B | - | ||
-0.50% | 1.64B | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- A170900 Stock
- Ratings Dong-A ST Co., Ltd.